1. Market Research
  2. > Lung Cancer – Pipeline Review, H1 2013

Lung Cancer – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 544 pages

Lung Cancer – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Cancer. Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Cancer.
- A review of the Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lung Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lung Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lung Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Lung Cancer - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
Introduction 11
Lung Cancer Overview 12
Therapeutics Development 13
Lung Cancer Therapeutics under Development by Companies 15
Lung Cancer Therapeutics under Investigation by Universities/Institutes 34
Late Stage Products 40
Mid Clinical Stage Products 41
Early Clinical Stage Products 42
Discovery and Pre-Clinical Stage Products 43
Lung Cancer Therapeutics - Products under Development by Companies 44
Lung Cancer Therapeutics - Products under Investigation by Universities/Institutes 76
Companies Involved in Lung Cancer Therapeutics Development 83
Lung Cancer - Therapeutics Assessment 293
Drug Profiles 301
Lung Cancer Therapeutics - Drug Profile Updates 433
Lung Cancer Therapeutics - Discontinued Products 485
Lung Cancer Therapeutics - Dormant Products 493
Lung Cancer - Product Development Milestones 525
Appendix 532



List of Tables

Number of Products Under Development for Lung Cancer, H1 2013 24
Products under Development for Lung Cancer - Comparative Analysis, H1 2013 25
Number of Products under Development by Companies, H1 2013 27
Number of Products under Development by Companies, H1 2013 (Contd..1) 28
Number of Products under Development by Companies, H1 2013 (Contd..2) 29
Number of Products under Development by Companies, H1 2013 (Contd..3) 30
Number of Products under Development by Companies, H1 2013 (Contd..4) 31
Number of Products under Development by Companies, H1 2013 (Contd..5) 32
Number of Products under Development by Companies, H1 2013 (Contd..6) 33
Number of Products under Development by Companies, H1 2013 (Contd..7) 34
Number of Products under Development by Companies, H1 2013 (Contd..8) 35
Number of Products under Development by Companies, H1 2013 (Contd..9) 36
Number of Products under Development by Companies, H1 2013 (Contd..10) 37
Number of Products under Development by Companies, H1 2013 (Contd..11) 38
Number of Products under Development by Companies, H1 2013 (Contd..12) 39
Number of Products under Development by Companies, H1 2013 (Contd..13) 40
Number of Products under Development by Companies, H1 2013 (Contd..14) 41
Number of Products under Development by Companies, H1 2013 (Contd..15) 42
Number of Products under Development by Companies, H1 2013 (Contd..16) 43
Number of Products under Development by Companies, H1 2013 (Contd..17) 44
Number of Products under Investigation by Universities/Institutes, H1 2013 46
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 47
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 48
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 49
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 50
Comparative Analysis by Late Stage Development, H1 2013 51
Comparative Analysis by Mid Clinical Stage Development, H1 2013 52
Comparative Analysis by Early Clinical Stage Development, H1 2013 53
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 54
Products under Development by Companies, H1 2013 55
Products under Development by Companies, H1 2013 (Contd..1) 56
Products under Development by Companies, H1 2013 (Contd..2) 57
Products under Development by Companies, H1 2013 (Contd..3) 58
Products under Development by Companies, H1 2013 (Contd..4) 59
Products under Development by Companies, H1 2013 (Contd..5) 60
Products under Development by Companies, H1 2013 (Contd..6) 61
Products under Development by Companies, H1 2013 (Contd..7) 62
Products under Development by Companies, H1 2013 (Contd..8) 63
Products under Development by Companies, H1 2013 (Contd..9) 64
Products under Development by Companies, H1 2013 (Contd..10) 65
Products under Development by Companies, H1 2013 (Contd..11) 66
Products under Development by Companies, H1 2013 (Contd..12) 67
Products under Development by Companies, H1 2013 (Contd..13) 68
Products under Development by Companies, H1 2013 (Contd..14) 69
Products under Development by Companies, H1 2013 (Contd..15) 70
Products under Development by Companies, H1 2013 (Contd..16) 71
Products under Development by Companies, H1 2013 (Contd..17) 72
Products under Development by Companies, H1 2013 (Contd..18) 73
Products under Development by Companies, H1 2013 (Contd..19) 74
Products under Development by Companies, H1 2013 (Contd..20) 75
Products under Development by Companies, H1 2013 (Contd..21) 76
Products under Development by Companies, H1 2013 (Contd..22) 77
Products under Development by Companies, H1 2013 (Contd..23) 78
Products under Development by Companies, H1 2013 (Contd..24) 79
Products under Development by Companies, H1 2013 (Contd..25) 80
Products under Development by Companies, H1 2013 (Contd..26) 81
Products under Development by Companies, H1 2013 (Contd..27) 82
Products under Development by Companies, H1 2013 (Contd..28) 83
Products under Development by Companies, H1 2013 (Contd..29) 84
Products under Development by Companies, H1 2013 (Contd..30) 85
Products under Development by Companies, H1 2013 (Contd..31) 86
Products under Investigation by Universities/Institutes, H1 2013 87
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 88
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 89
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 90
Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 91
Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 92
Products under Investigation by Universities/Institutes, H1 2013 (Contd..6) 93
Bristol-Myers Squibb Company, H1 2013 94
Boehringer Ingelheim GmbH, H1 2013 95
F. Hoffmann-La Roche Ltd., H1 2013 96
Kyowa Hakko Kirin Co., Ltd., H1 2013 97
Celsion Corporation, H1 2013 98
Helix BioPharma Corp., H1 2013 99
Shionogi and Co., Ltd., H1 2013 100
Amgen Inc., H1 2013 101
Sanofi-Aventis, H1 2013 102
AstraZeneca PLC, H1 2013 103
Eli Lilly and Company, H1 2013 104
Viralytics Ltd., H1 2013 105
GlaxoSmithKline plc, H1 2013 106
Genentech, Inc., H1 2013 107
Nektar Therapeutics, H1 2013 108
Bavarian Nordic A/S, H1 2013 109
MedImmune LLC, H1 2013 110
Isis Pharmaceuticals, Inc., H1 2013 111
Gilead Sciences, Inc., H1 2013 112
Daiichi Sankyo Company, Ltd, H1 2013 113
Merck and Co., Inc., H1 2013 114
AbGenomics International, Inc., H1 2013 115
FASgen, Inc., H1 2013 116
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 117
AandG Pharmaceutical, Inc., H1 2013 118
Infinity Pharmaceuticals, Inc., H1 2013 119
Takeda Pharmaceutical Company Limited, H1 2013 120
Amorfix Life Sciences Ltd., H1 2013 121
Ipsen S.A., H1 2013 122
Celltrion, Inc., H1 2013 123
ZIOPHARM Oncology, Inc., H1 2013 124
Novartis AG, H1 2013 126
Astellas Pharma Inc., H1 2013 127
Chong Kun Dang Pharmaceutical, H1 2013 128
Daewoong Pharmaceutical Co., Ltd., H1 2013 129
Eisai Co., Ltd., H1 2013 130
ImmunoGen, Inc., H1 2013 131
Laboratoires Pierre Fabre SA, H1 2013 132
Nippon Kayaku Co., Ltd., H1 2013 133
Ono Pharmaceutical Co., Ltd., H1 2013 134
Pfizer Inc., H1 2013 135
SuperGen, Inc., H1 2013 136
Taiho Pharmaceutical Co., Ltd., H1 2013 137
Teva Pharmaceutical Industries Limited, H1 2013 138
Cell Therapeutics, Inc., H1 2013 139
Santaris Pharma A/S, H1 2013 140
Exelixis, Inc., H1 2013 141
Aduro BioTech, H1 2013 142
Menarini Group, H1 2013 143
Cyclacel Pharmaceuticals Inc., H1 2013 144
Alfacell Corporation, H1 2013 145
Celgene Corporation, H1 2013 146
Onyx Pharmaceuticals, Inc., H1 2013 147
Bayer AG, H1 2013 148
AntiCancer, Inc., H1 2013 149
Geron Corporation, H1 2013 150
Aeolus Pharmaceuticals, Inc., H1 2013 151
Merck KGaA, H1 2013 152
Neogenix Oncology Corporation, H1 2013 153
Alchemia Limited, H1 2013 154
EntreMed, Inc., H1 2013 155
Hana Biosciences, Inc., H1 2013 156
Celldex Therapeutics, Inc., H1 2013 157
Momenta Pharmaceuticals, Inc., H1 2013 158
ValiRx Plc, H1 2013 159
AEterna Zentaris Inc., H1 2013 160
ImmunoCellular Therapeutics, Ltd., H1 2013 161
Idera Pharmaceuticals, Inc., H1 2013 162
Ariad Pharmaceuticals, Inc., H1 2013 163
Lorus Therapeutics Inc, H1 2013 164
Basilea Pharmaceutica Ltd., H1 2013 165
Benitec Ltd., H1 2013 166
MethylGene Inc, H1 2013 167
Bionomics Limited, H1 2013 168
Northwest Biotherapeutics, Inc., H1 2013 169
Cleveland BioLabs, Inc., H1 2013 170
Oncolytics Biotech Inc., H1 2013 171
Oncothyreon Inc, H1 2013 172
Compugen Ltd., H1 2013 173
OXiGENE, Inc., H1 2013 174
Patrys Limited, H1 2013 175
Peregrine Pharmaceuticals, Inc., H1 2013 176
Critical Outcome Technologies Inc., H1 2013 177
Curis, Inc., H1 2013 178
ARQULE, INC, H1 2013 179
Cytokinetics, Inc, H1 2013 180
Telik, Inc., H1 2013 181
TopoTarget A/S, H1 2013 182
CytRx Corporation, H1 2013 183
Regeneron Pharmaceuticals, Inc., H1 2013 184
Oncogenex Pharmaceuticals, Inc., H1 2013 185
Dendreon Corporation, H1 2013 186
ProMetic Life Sciences Inc., H1 2013 187
MOLOGEN AG, H1 2013 189
Innocell Corporation, H1 2013 190
Quest PharmaTech Inc., H1 2013 191
Threshold Pharmaceuticals, Inc., H1 2013 192
Synta Pharmaceuticals Corp., H1 2013 193
Natco Pharma Limited, H1 2013 194
Sareum Holdings plc, H1 2013 195
Simcere Pharmaceutical Group, H1 2013 196
Sun Pharma Advanced Research Company, H1 2013 197
Rexahn Pharmaceuticals, Inc., H1 2013 198
Scancell Holdings Plc, H1 2013 199
MabVax Therapeutics, Inc., H1 2013 200
Nanobiotix, H1 2013 201
Morphotek, Inc., H1 2013 202
Cancer Research Technology Limited, H1 2013 203
Oryzon, H1 2013 204
Spectrum Pharmaceuticals, Inc., H1 2013 205
Chipscreen Biosciences Ltd, H1 2013 207
CIMAB S.A., H1 2013 208
Supratek Pharma Inc., H1 2013 209
Bionucleon Srl, H1 2013 210
Fusion Antibodies Ltd, H1 2013 212
GANYMED Pharmaceuticals AG, H1 2013 213
Ora Bio Ltd., H1 2013 214
Philogen S.p.A., H1 2013 215
NovaRx Corporation, H1 2013 216
Actis Biologics, Inc, H1 2013 217
Multimmune GmbH, H1 2013 218
Nerviano Medical Sciences S.r.l., H1 2013 219
Med Discovery SA, H1 2013 220
Cadila Pharmaceuticals Ltd., H1 2013 222
Hutchison MediPharma Limited, H1 2013 223
immatics biotechnologies GmbH, H1 2013 224
Vaxon Biotech, H1 2013 225



List of Figures

Number of Products under Development for Lung Cancer, H1 2013 24
Products under Development for Lung Cancer - Comparative Analysis, H1 2013 25
Products under Development by Companies, H1 2013 26
Products under Investigation by Universities/Institutes, H1 2013 45
Late Stage Products, H1 2013 51
Mid Clinical Stage Products, H1 2013 52
Early Clinical Stage Products, H1 2013 53
Discovery and Pre-Clinical Stage Products, H1 2013 54
Assessment by Monotherapy Products, H1 2013 304
Assessment by Combination Products, H1 2013 305
Assessment by Route of Administration, H1 2013 306
Assessment by Stage and Route of Administration, H1 2013 307
Assessment by Molecule Type, H1 2013 309
Assessment by Stage and Molecule Type, H1 2013 310

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.